自体肿瘤裂解物负载树突细胞疫苗与延长新诊断及复发胶质母细胞瘤患者生存的关联:一项3期前瞻性外部对照队列试验
该3期前瞻性外部对照非随机试验在4国94个中心纳入331例胶质母细胞瘤患者,比较DCVax-L联合标准治疗与同期匹配外部对照的总生存。新诊断患者232例接受DCVax-L,中位OS 19.3个月 vs 对照16.5个月(HR=0.80,P=.002);复发患者64例,中位OS 13.2个月 vs 对照7.8个月(HR=0.58,P<.001)。
要点
- 新诊断胶质母细胞瘤接受DCVax-L联合标准治疗,中位OS 19.3个月 vs 外部对照16.5个月,HR=0.80。
- 复发胶质母细胞瘤接受DCVax-L,中位OS 13.2个月 vs 外部对照7.8个月,HR=0.58。
- 新诊断MGMT甲基化患者接受DCVax-L较外部对照生存改善,HR=0.74(98% CI 0.55-1.00,P=.03)。
核心结论
- 在新诊断和复发胶质母细胞瘤患者中,标准治疗基础上加用DCVax-L,与仅接受标准治疗的同期匹配外部对照相比,获得有临床意义且统计学显著的生存延长。
研究设计与样本
- 3期前瞻性外部对照非随机试验,比较DCVax-L联合标准治疗与同期匹配外部对照的总生存。
- 试验在4个国家的94个中心开展,时间为2007年8月至2015年11月,数据分析时间为2020年10月至2021年9月。
- 共入组331例患者,其中232例随机分配至DCVax-L组,99例分配至安慰剂组;外部对照来自其他正式随机临床试验的对照组。
主要发现
- 232例新诊断胶质母细胞瘤患者接受DCVax-L,中位OS为19.3个月(95% CI 17.5-21.3),自随机化起算,自手术起算为22.4个月;外部对照中位OS为16.5个月(95% CI 16.0-17.5),自随机化起算(HR=0.80;98% CI 0.00-0.94;P=.002)。
- 新诊断患者自随机化起算48个月生存率为15.7% vs 9.9%,60个月生存率为13.0% vs 5.7%。
- 64例复发胶质母细胞瘤患者接受DCVax-L,自复发起算中位OS为13.2个月(95% CI 9.7-16.8);外部对照中位OS为7.8个月(95% CI 7.2-8.2)(HR=0.58;98% CI 0.00-0.76;P<.001)。
- 复发后24个月和30个月生存率分别为20.7% vs 9.6%和11.1% vs 5.1%。
- 新诊断MGMT甲基化患者接受DCVax-L较外部对照生存改善(HR=0.74;98% CI 0.55-1.00;P=.03)。
关键数值与推荐
- 新诊断胶质母细胞瘤:DCVax-L组中位OS 19.3个月 vs 外部对照16.5个月,HR=0.80(98% CI 0.00-0.94;P=.002)。
- 复发胶质母细胞瘤:DCVax-L组中位OS 13.2个月 vs 外部对照7.8个月,HR=0.58(98% CI 0.00-0.76;P<.001)。
- 新诊断MGMT甲基化患者:DCVax-L组较外部对照HR=0.74(98% CI 0.55-1.00;P=.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. OBJECTIVE: To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021. INTERVENTIONS: The active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies. MAIN OUTCOMES AND MEASURES: The primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials. RESULTS: A total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after recurrence was 20.7% vs 9.6% and 11.1% vs 5.1%, respectively. Survival was improved in patients with nGBM with methylated MGMT receiving DCVax-L compared with external control patients (HR, 0.74; 98% CI, 0.55-1.00; P = .03). CONCLUSIONS AND RELEVANCE: In this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00045968.
引用
- Liau LM, Ashkan K, Brem S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023. PMID: 36394838. doi:10.1001/jamaoncol.2022.5370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。